{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:49:56Z","timestamp":1759693796116},"reference-count":0,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,1,4]],"date-time":"2016-01-04T00:00:00Z","timestamp":1451865600000},"content-version":"vor","delay-in-days":14247,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[1977,1]]},"abstract":"<jats:p>Fenoprofen calcium (2,400 mg\/day) or aspirin (3,900 mg\/day) was administered in double\u2010blind fashion to 20 rheumatoid patients during 6 months of gold induction therapy, and to 20 rheumatoid patiellts not receiving gold. Among both the gold\u2010treated and nongold\u2010treated patients, the fenoprofen and aspirin groups improved equally in all but one parameter of disease activity. Fenoprofen and aspirin did not differ significantly in the observed prevalences of abdominal discomfort, guaiac\u2010positive stools, or peptic ulcers. Aspirin was associated with significantly higher mean serum glutamic oxaloacetic transaminase (SGOT) levels than fenoprofen, but only among patients undergoing gold induction. Comparison of efficacy parameters between patients treated with gold and patients treated with oral drugs alone revealed significant differences famring gold.<\/jats:p>","DOI":"10.1002\/cpt197721152","type":"journal-article","created":{"date-parts":[[2016,1,5]],"date-time":"2016-01-05T01:46:09Z","timestamp":1451958369000},"page":"52-61","source":"Crossref","is-referenced-by-count":20,"title":["Fenoprofen, aspirin, and gold induction in rheumatoid arthritis"],"prefix":"10.1111","volume":"21","author":[{"given":"John D.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald L.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inez R.","family":"Ruchte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John S.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,4]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt197721152","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt197721152","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt197721152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:31:27Z","timestamp":1699363887000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt197721152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1977,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1977,1]]}},"alternative-id":["10.1002\/cpt197721152"],"URL":"https:\/\/doi.org\/10.1002\/cpt197721152","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[1977,1]]}}}